Merus (NASDAQ:MRUS) Receives $85.92 Average Target Price from Brokerages

Merus (NASDAQ:MRUS) has been assigned a consensus rating of “Buy” from the sixteen analysts that are presently covering the firm, MarketBeat reports. Fourteen equities research analysts have rated the stock with a buy recommendation and two have issued a strong buy recommendation on the company. The average twelve-month price objective among analysts that have covered the stock in the last year is $85.92.

Several brokerages have recently commented on MRUS. Needham & Company LLC reaffirmed a “buy” rating and set a $85.00 price objective on shares of Merus in a research report on Monday, December 9th. Piper Sandler assumed coverage on shares of Merus in a research report on Thursday, February 13th. They issued an “overweight” rating and a $84.00 price target for the company. Wells Fargo & Company assumed coverage on shares of Merus in a research report on Friday, February 7th. They issued an “overweight” rating and a $91.00 price target for the company. HC Wainwright reissued a “buy” rating and issued a $85.00 price target on shares of Merus in a research report on Monday, December 2nd. Finally, Guggenheim reissued a “buy” rating on shares of Merus in a research report on Wednesday, February 12th.

Merus Stock Down 0.5 %

Shares of MRUS stock opened at $47.37 on Friday. The company has a market cap of $3.24 billion, a price-to-earnings ratio of -11.99 and a beta of 1.11. Merus has a 52 week low of $37.77 and a 52 week high of $61.61. The firm has a 50 day moving average of $41.72 and a 200-day moving average of $46.93.

Institutional Investors Weigh In On Merus

A number of hedge funds have recently made changes to their positions in the business. GF Fund Management CO. LTD. bought a new stake in shares of Merus during the 4th quarter worth $60,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its position in shares of Merus by 17.3% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 98,744 shares of the biotechnology company’s stock valued at $4,152,000 after buying an additional 14,544 shares during the period. Woodline Partners LP increased its position in shares of Merus by 0.3% during the fourth quarter. Woodline Partners LP now owns 1,188,518 shares of the biotechnology company’s stock valued at $49,977,000 after buying an additional 3,593 shares during the period. Squarepoint Ops LLC bought a new position in shares of Merus in the fourth quarter worth approximately $817,000. Finally, Wexford Capital LP increased its position in shares of Merus by 26.2% in the fourth quarter. Wexford Capital LP now owns 40,386 shares of the biotechnology company’s stock worth $1,698,000 after purchasing an additional 8,386 shares during the last quarter. 96.14% of the stock is currently owned by institutional investors.

Merus Company Profile

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1.